NOVOLOG MIX 50/50 Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NOVOLOG MIX 50/50
High Confidence Patents: | 12 |
Applicants: | 1 |
BLAs: | 1 |
Recent Clinical Trials: | See clinical trials for NOVOLOG MIX 50/50 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NOVOLOG MIX 50/50 |
Recent Clinical Trials for NOVOLOG MIX 50/50
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Amphastar Pharmaceuticals, Inc. | Phase 2/Phase 3 |
The Cleveland Clinic | Phase 4 |
Boston Medical Center | Phase 3 |
Recent Litigation for NOVOLOG MIX 50/50
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
NOVO NORDISK INC. v. RIO BIOPHARMACEUTICALS, INC. | 2024-01-19 |
NOVO NORDISK INC. v. DR. REDDY'S LABORATORIES, LTD. | 2023-11-08 |
Novo Nordisk Inc. v. Mylan Institutional LLC | 2019-08-22 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NOVOLOG MIX 50/50 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NOVOLOG MIX 50/50 Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | NOVOLOG MIX 50/50 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021810 | ⤷ Free Trial | 2013-08-20 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG MIX 50/50 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021810 | ⤷ Free Trial | 2014-04-08 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG MIX 50/50 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021810 | ⤷ Free Trial | 2014-12-02 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG MIX 50/50 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021810 | ⤷ Free Trial | 2013-06-21 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG MIX 50/50 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021810 | ⤷ Free Trial | 2013-06-21 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NOVOLOG MIX 50/50 Derived from Patent Text Search
No patents found based on company disclosures
International Patents for NOVOLOG MIX 50/50
Country | Patent Number | Estimated Expiration |
---|---|---|
Austria | E113061 | ⤷ Free Trial |
Hungary | P9904031 | ⤷ Free Trial |
Philippines | 25772 | ⤷ Free Trial |
Greece | 3030130 | ⤷ Free Trial |
Japan | 2009235075 | ⤷ Free Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVOLOG MIX 50/50
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
41/2005 | Austria | ⤷ Free Trial | PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005 |
CA 2005 00047 | Denmark | ⤷ Free Trial | PRODUCT NAME: INSULIN ASPART, PROTAMINKRYSTALLISERET |
C00214826/01 | Switzerland | ⤷ Free Trial | FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
132000900885237 | Italy | ⤷ Free Trial | AUTHORISATION NUMBER(S) AND DATE(S): (VEDI NOTE), 20000801;- - -, 20181206 |
SZ 40/2005 | Austria | ⤷ Free Trial | PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LĂ–SLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHĂ„LTNIS 50:50 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for NovoLog Mix 50/50
More… ↓